Home > Healthcare > Pharmaceuticals > Finished Drug Form > Local Anesthesia Market

Local Anesthesia Market Trends

Report ID: GMI7699
Published Date: Dec 2023
Report Format: PDF

Download Free Sample

Local Anesthesia Market Trends

The rising geriatric population, prone to various medical interventions, contributes to market growth. Advancements in surgery and intensive care have led more of this aging population to seek surgical procedures. Studies suggest that around 53% of surgeries involve individuals aged 65 and above. Therefore, anticipated growth in surgeries among the elderly, coupled with anesthesia drug usage in moderately surgical procedures especially dental, is expected to drive market expansion.
In addition, growing emphasis on pain management drugs and efficacy, further boosts the adoption of local anesthesia. For instance, in May 2021, Heron Therapeutics, Inc. has gained FDA approval for ZYNRELEF extended-release solution in adults, offering prolonged post-surgical pain relief for up to 72 hours following procedures such as bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty. As the only extended-release dual-acting local anesthetic, this approval indicates a significant advancement in pain management for patients and healthcare providers.

Furthermore, technological advancements, research activities, increasing chronic conditions, and augmented government support with enhanced R&D funding collectively contribute to the expansion of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of local anesthesia was exceeded USD 4.2 billion in 2023 and is expected to reach USD 6.1 billion by 2032, fueled by rising number of minimally invasive surgeries, and providing precise pain relief in surgical procedures especially in cosmetic surgery.

The lidocaine segment revenue is expected to reach USD 2 billion by 2032, owing to its short-acting properties due to which it is extensively employed for local or regional anesthesia during various medical procedures.

The hospital segment accounted for USD 2.3 billion in 2023 and will grow significantly through 2032, as they are serving as key hubs for various medical procedures requiring localized pain management.

Pfizer Inc., GE Healthcare, Baxter International Inc., Fresenius Kabi, B. Braun Melsungen AG, Piramal, AbbVie Inc., Pacira BioSciences, Aspen Pharmacare Holdings Ltd, Septodont, and Ultracain.